Charles Goodwin
April 11, 2022 | New York Law Journal
Psychedelic Startups Set To Capitalize on Evolving Regulatory LandscapeThere has been an explosion of renewed interest in the psychedelic space, specifically in the medical application of psychedelic substances as a therapeutic treatment for mental and emotional disorder. This has caught the eye of some of the largest names in private equity, and investor enthusiasm is not going unnoticed.
By Jason Rimland and Charles Goodwin
9 minute read
Trending Stories
- 1Don’t Blow It: 10 Lessons From 10 Years of Nonprofit Whistleblower Policies
- 2AIAs: A Look At the Future of AI-Related Contracts
- 3Litigators of the Week: A $630M Antitrust Settlement for Automotive Software Vendors—$140M More Than Alleged Overcharges
- 4Litigator of the Week Runners-Up and Shout-Outs
- 5Linklaters Hires Four Partners From Patterson Belknap
